Actively Recruiting
mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer Refractory to Chemotherapy
Led by Fudan University · Updated on 2025-08-07
30
Participants Needed
1
Research Sites
204 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to evaluate the efficacy of mFOLFIRINOX plus radiotherapy to Patients with CA19-9-normal Advanced Pancreatic Cancer refractory to chemotherapy.
CONDITIONS
Official Title
mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer Refractory to Chemotherapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Able to understand and willing to sign informed consent
- Age 18 to 80 years
- ECOG performance status between 0 and 2
- Confirmed advanced pancreatic adenocarcinoma by tissue or cell analysis
- Refractory to at least one chemotherapy treatment and no prior radiotherapy
- Locally advanced or metastatic pancreatic cancer
- Baseline serum CA19-9 ≤ 37 U/mL, CEA ≤ 5.2 ng/mL, and CA125 ≤ 35 U/mL
- At least one measurable tumor lesion per RECIST criteria
- Expected survival of 3 months or longer
- Adequate organ function based on blood tests
- Women of childbearing potential and men agree to use contraception during study
You will not qualify if you...
- Pregnant or nursing women
- Primary pancreatic cancer
- Baseline serum CA19-9 > 37 U/mL, CEA > 5.2 ng/mL, or CA125 > 35 U/mL
- Non-adenocarcinoma pancreatic cancer confirmed by pathology
- Digestive tract inflammation such as pancreatitis, cholecystitis, or cholangitis
- Severe uncontrollable diseases affecting study compliance or results
- Renal insufficiency or dialysis
- Serious illnesses that could affect treatment safety
- Allergy to oxaliplatin or other chemotherapy drugs
- Unwillingness or inability to follow study procedures
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Shanghai Cancer Center
Shanghai, Shanghai Municipality, China, 200032
Actively Recruiting
Research Team
Y
Ying Yang, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here